Healthy men test how new cancer drug moves through the body
NCT ID NCT05879991
First seen Nov 01, 2025
Summary
This completed Phase 1 trial enrolled 15 healthy men to understand how the experimental drug zongertinib is absorbed, broken down, and eliminated from the body. In one part, participants took a radioactive oral solution so researchers could track the drug in urine and stool. In another part, they received both a tablet and a tiny intravenous dose to measure how much of the drug reaches the bloodstream. The study was not designed to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICON
Groningen, 9728 NZ, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zongertinib
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.